StockNews.com initiated coverage on shares of Maximus (NYSE:MMS – Get Rating) in a research report released on Thursday morning. The brokerage issued a hold rating on the health services provider’s stock.
Other equities analysts have also recently issued reports about the stock. Raymond James raised their target price on shares of Maximus from $80.00 to $100.00 and gave the company an outperform rating in a research note on Thursday, February 9th. TheStreet raised shares of Maximus from a c+ rating to a b- rating in a research note on Thursday, December 8th.
Maximus Price Performance
Shares of NYSE MMS traded down $1.12 during midday trading on Thursday, reaching $74.03. The stock had a trading volume of 694,148 shares, compared to its average volume of 356,562. The stock has a 50-day moving average of $77.47 and a 200-day moving average of $68.67. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.68 and a current ratio of 1.68. The company has a market capitalization of $4.50 billion, a price-to-earnings ratio of 23.96 and a beta of 0.69. Maximus has a 12-month low of $54.46 and a 12-month high of $85.25.
Maximus Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, February 28th. Shareholders of record on Wednesday, February 15th were given a dividend of $0.28 per share. The ex-dividend date was Tuesday, February 14th. This represents a $1.12 annualized dividend and a yield of 1.51%. Maximus’s dividend payout ratio (DPR) is currently 36.25%.
Insider Buying and Selling at Maximus
In other Maximus news, insider Ilene R. Baylinson sold 9,550 shares of the stock in a transaction on Friday, February 10th. The shares were sold at an average price of $82.74, for a total transaction of $790,167.00. Following the completion of the transaction, the insider now owns 10,044 shares in the company, valued at $831,040.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is owned by company insiders.
Hedge Funds Weigh In On Maximus
Institutional investors have recently bought and sold shares of the business. Quadrant Capital Group LLC lifted its position in Maximus by 119.8% during the fourth quarter. Quadrant Capital Group LLC now owns 389 shares of the health services provider’s stock valued at $29,000 after purchasing an additional 212 shares during the last quarter. Householder Group Estate & Retirement Specialist LLC bought a new stake in shares of Maximus in the 3rd quarter worth about $26,000. Bessemer Group Inc. lifted its holdings in shares of Maximus by 577.6% in the 3rd quarter. Bessemer Group Inc. now owns 576 shares of the health services provider’s stock worth $33,000 after acquiring an additional 491 shares during the last quarter. Fifth Third Bancorp lifted its holdings in shares of Maximus by 588.1% in the 4th quarter. Fifth Third Bancorp now owns 578 shares of the health services provider’s stock worth $42,000 after acquiring an additional 494 shares during the last quarter. Finally, Wipfli Financial Advisors LLC bought a new stake in shares of Maximus in the 3rd quarter worth about $47,000. Institutional investors own 97.41% of the company’s stock.
Maximus Company Profile
MAXIMUS, Inc engages in the operation of government health and human services programs, and the provision of technology solutions to government. It operates through the following segments: U.S. Services, U.S. Federal Services, and Outside the U.S. The U.S. Services segment offers business process services (BPS), appeals and assessments, and related consulting work for U.S.
- Get a free copy of the StockNews.com research report on Maximus (MMS)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.